Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 4/20 | 0.33 |
| ▸ | CFD | P00746 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15145225 | 1.00 | PIK3CA (0.33) | PIK3CAMTORDPP4CFD | |
| SCHEMBL26112319 | 1.00 | PIK3CA (0.33) | PIK3CAMTORDPP4CFD | |
| SCHEMBL3298328 | 1.00 | PIK3CA (0.33) | PIK3CAMTORDPP4CFD | |
| SCHEMBL26607531 | 0.83 | ATM (0.31) | DPP4 | |
| SCHEMBL27156471 | 0.83 | ATM (0.31) | DPP4 | |
| SCHEMBL1759463 | 0.83 | ATM (0.31) | DPP4 | |
| SCHEMBL4102771 | 0.83 | ATM (0.31) | DPP4 | |
| SCHEMBL30985474 | 0.83 | ATM (0.31) | DPP4 | |
| SCHEMBL31527632 | 0.83 | ATM (0.31) | DPP4 | |
| SCHEMBL3265345 | 0.81 | PREP (0.37) | DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2505578-B1 | Methods and Compounds for Producing Dipeptidyl Peptidase IV Inhibitors and Intermediates thereof | ASTRAZENECA AB (SE) | 2014-09-24 | — | — | EP | claimed |
| EP-2517706-B1 | Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof | ASTRAZENECA AB (SE) | 2014-06-25 | — | — | EP | claimed |
| EP-2517706-A2 | Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof | Bristol-Myers Squibb Company (US) | 2012-10-31 | — | — | EP | claimed |
| EP-2505578-A2 | Methods and Compounds for Producing Dipeptidyl Peptidase IV Inhibitors and Intermediates thereof | Bristol-Myers Squibb Company (US) | 2012-10-03 | — | — | EP | claimed |
| EP-3000893-A2 | PROCESS FOR PREPARING DIPEPTIDYL PEPTIDASE IV INHIBITORS AND INTERMEDIATES THEREFOR | AstraZeneca AB (SE) | 2016-03-30 | — | — | EP | disclosed |
| EP-2894227-A2 | Process for preparing dipeptidyl peptidase iv inhibitors and intermediates therefor | AstraZeneca AB (SE) | 2015-07-15 | — | — | EP | disclosed |
| US-8809024-B2 | Process for preparing dipeptidyl peptidase IV inhibitors and intermediates therefor | ASTRAZENECA AB (SE) | 2014-08-19 | — | — | US | disclosed |
| US-8361761-B2 | Process for preparing dipeptidyl peptidase IV inhibitors and intermediates therefor | BRISTOL MYERS-SQUIBB COMPANY (US) | 2013-01-29 | — | — | US | disclosed |
| US-20120276600-A1 | Process For Preparing Dipeptidyl Peptidase IV Inhibitors And Intermediates Therefor | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-01 | — | — | US | disclosed |
| US-8222009-B2 | Process for preparing dipeptidyl peptidase IV inhibitors and intermediates therefor | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-07-17 | — | — | US | disclosed |
| US-20100291642-A1 | Process For Preparing Dipeptidyl Peptidase IV Inhibitors And Intermediates Therefor | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-11-18 | — | — | US | disclosed |
| US-7741082-B2 | Process for preparing dipeptidyl peptidase IV inhibitors and intermediates therefor | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-22 | — | — | US | disclosed |
| US-7611880-B2 | Enzymatic ammonolysis process for the preparation of intermediates for DPP IV inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-11-03 | — | — | US | disclosed |
| US-20070207527-A1 | ENZYMATIC AMMONOLYSIS PROCESS FOR THE PREPARATION OF INTERMEDIATES FOR DPP IV INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-09-06 | — | — | US | disclosed |
| US-7223573-B2 | Enzymatic ammonolysis process for the preparation of intermediates for DPP IV inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-29 | — | — | US | disclosed |
| US-20050260712-A1 | Process for preparing dipeptidyl peptidase IV inhibitors and intermediates therefor | ASTRAZENECA AB (SE) | 2005-11-24 | — | — | US | disclosed |
| US-20050256019-A1 | Enzymatic ammonolysis process for the preparation of intermediates for DPP IV inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050260712-A1 | Process for preparing dipeptidyl peptidase IV inhibitors and intermediates therefor | DNPEP, DPP4, PEPD | PIK3CA 2381/4885MTOR 2065/4885DPP4 2/4885 |
| US-20120276600-A1 | Process For Preparing Dipeptidyl Peptidase IV Inhibitors And Intermediates Therefor | DNPEP, DPP4, DPP8 | PIK3CA 2514/4885MTOR 2057/4885DPP4 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.